Biosimilars: the 'future' of biologic therapy?
Related Experiment Video
Updated: Jun 10, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Nitin Ranjan1, Vikram K Mahajan, Monika Misra
1Kaveri Apartments, Aligarh, Uttar Pradesh, India. drnitinranjan@gmail.com
Abstract:
The introduction of a number of biologic therapies to the market has revolutionized therapeutics in dermatology. However, the patents protecting their manufacture are about to lapse, and follow-on generic products, known as biosimilars, are about to flood the pharmaceutical market. The 'biosimilars' are different from the generic products of conventional drugs in terms of efficacy, safety and immunogenicity. This awareness is essential for their proper prescription and the safety of patients. This article intends to serve as a primer for dermatologists in their understanding of biosimilars.
More Related Videos
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Microorganisms in Medicine and Therapeutics
Bioequivalence: Overview
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Bioequivalence studies: Biowaivers
Biopharmaceutical Factors Influencing Drug Product Design: Overview